Why the study?
Does the duration of exposure to ARBs during pregnancy affect the risk of adverse fetal outcomes?
Does the duration of exposure to ARBs during pregnancy affect the risk of adverse fetal outcomes?
Prolonged exposure to ARBs beyond the first trimester of pregnancy is associated with a significantly increased risk of adverse fetal outcomes.
Prompt ARB discontinuation upon pregnancy detection is advised; extends evidence linking exposure duration to fetal outcomes.
OBJECTIVE: To describe the case of a woman exposed to angiotensin-II receptor blockers (ARBs) in the preconceptional period and to systematically review the literature on the safety of these drugs when used by pregnant women. METHODS: The case was identified at the Korean Motherisk Program (Seoul). For the systematic review, we searched the PubMed for case reports, case series, and post-marketing surveys. RESULTS: A hypertensive woman was exposed to irbesartan prior to conception. The embryo had delayed development of upper and lower extremities and decreased digital groove. A karyotype identified a 45,XO Turner syndrome. The patient had a spontaneous abortion. Including the case reported here, 64 published cases were identified in total; 57.8% had favorable and 42.2% had unfavorable outcomes. Duration of treatment during pregnancy among women who had adverse fetal outcomes was 26.3 +/- 10.5 weeks (mean +/- SD), compared with 17.3 +/- 11.6 weeks in those who had favorable outcomes (p = 0.04). CONCLUSIONS: Exposure to ARBs for a period longer than the first trimester of pregnancy appears to be associated with a high risk for adverse fetal outcomes.
No takes yet. Share an insight, caveat, or question.
Velázquez-Armenta et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: